Celgene (NASDAQ:CELG) will be issuing its quarterly earnings data before the market opens on Thursday, January 25th. Analysts expect the company to announce earnings of $1.94 per share for the quarter. Celgene has set its FY17 guidance at $7.30-7.35 EPS.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the business earned $1.58 EPS. The company’s revenue was up 10.2% on a year-over-year basis. On average, analysts expect Celgene to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Shares of Celgene (NASDAQ CELG) opened at $102.02 on Thursday. Celgene has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The firm has a market cap of $80,320.00, a price-to-earnings ratio of 24.06, a PEG ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

CELG has been the topic of a number of analyst reports. Royal Bank of Canada reduced their price objective on shares of Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a report on Friday, October 27th. Leerink Swann reiterated a “buy” rating and set a $156.00 price target on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley cut their price target on shares of Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a research note on Monday, October 23rd. SunTrust Banks cut their price target on shares of Celgene from $156.00 to $127.00 and set a “buy” rating on the stock in a research note on Friday, October 27th. Finally, William Blair reiterated an “outperform” rating on shares of Celgene in a research note on Friday, October 20th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Celgene has an average rating of “Buy” and an average target price of $130.95.

A number of hedge funds have recently added to or reduced their stakes in the stock. Castleark Management LLC purchased a new stake in Celgene during the second quarter worth about $30,282,000. Piedmont Investment Advisors LLC boosted its holdings in Celgene by 1.5% during the second quarter. Piedmont Investment Advisors LLC now owns 165,696 shares of the biopharmaceutical company’s stock worth $21,519,000 after buying an additional 2,522 shares in the last quarter. Chiron Investment Management LLC boosted its holdings in Celgene by 38.4% during the second quarter. Chiron Investment Management LLC now owns 131,800 shares of the biopharmaceutical company’s stock worth $17,117,000 after buying an additional 36,600 shares in the last quarter. Scotia Capital Inc. boosted its holdings in Celgene by 21.0% during the second quarter. Scotia Capital Inc. now owns 69,457 shares of the biopharmaceutical company’s stock worth $9,020,000 after buying an additional 12,058 shares in the last quarter. Finally, Cypress Capital Group boosted its holdings in Celgene by 12.6% during the second quarter. Cypress Capital Group now owns 39,742 shares of the biopharmaceutical company’s stock worth $5,162,000 after buying an additional 4,450 shares in the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/18/celgene-celg-scheduled-to-post-quarterly-earnings-on-thursday.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Earnings History for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.